Universe Pharmaceuticals INC (UPC)

UPC Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	5.29	5.71	8.08	10.06	3.18
Short-Term Investments	13.22	13.15	13.73	0	0
Cash & Cash Equivalents	18.5	18.86	21.8	10.06	3.18
Cash Growth	-1.89%	-13.50%	116.77%	216.56%	-
Receivables	10.91	15.2	18.55	10.87	6.42
Inventory	3.34	2.21	2.46	1.91	2.62
Other Current Assets	4.05	5.24	7.67	0.44	0.02
Total Current Assets	36.81	41.51	50.48	23.28	12.23
Property, Plant & Equipment	3.7	4.25	4.68	4.43	4.57
Long-Term Investments	0.69	0.7	0.74	0.74	0.7
Goodwill and Intangibles	0.15	0.16	0.18	0.17	0.17
Other Long-Term Assets	11.94	12.92	14.06	0.19	0.17
Total Long-Term Assets	16.48	18.03	19.66	5.52	5.61
Total Assets	53.29	59.54	70.14	28.8	17.84
Accounts Payable	5.13	6.45	5.33	3.65	1.99
Current Debt	5.48	3.94	4.33	2.65	2.52
Other Current Liabilities	3.15	2.71	1.55	1.71	0.94
Total Current Liabilities	13.75	13.1	11.21	8	5.45
Total Liabilities	13.75	13.1	11.21	8	5.45
Total Debt	5.48	3.94	4.33	2.65	2.52
Debt Growth	39.28%	-9.19%	63.81%	4.93%	-
Retained Earnings	10.16	16.32	25.06	13.74	6.18
Comprehensive Income	-2.41	-1.67	2.09	0.9	0.03
Shareholders' Equity	39.53	46.44	58.93	20.8	12.38
Net Cash / Debt	13.02	14.92	17.47	7.41	0.66
Net Cash / Debt Growth	-12.75%	-14.57%	135.68%	1030.73%	-
Net Cash Per Share	3.59	4.12	5.52	2.78	0.25
Working Capital	23.06	28.41	39.27	15.28	6.78
Book Value Per Share	10.91	12.81	18.63	7.80	4.64

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).